Vaccines for the prevention against the threat of MERS-CoV

Expert Review of Vaccines

Volumn 15, Issue 9, 2016, Pages 1123-1134

  Du, Lanying ^a   Tai, Wanbo ^a,b   Zhou, Yusen ^b   Jiang, Shibo ^a,c  

^a NEW YORK BLOOD CENTER   (United States)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Animal models; immune responses; MERS; MERS CoV; neutralizing antibody; protection; spike protein; vaccines

Indexed keywords

DNA; DNA PRIME; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS VACCINE; NANOPARTICLE; PROTEIN; RECOMBINANT VACCINE; SUBUNIT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE; VIRUS VECTOR;

CLINICAL TRIAL (TOPIC); CORONAVIRUS INFECTION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IN VIVO STUDY; INFECTION PREVENTION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS INFECTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; CORONAVIRUS INFECTIONS; DISEASE MODEL; DRUG DEVELOPMENT; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; TRENDS;

ANIMALS; CORONAVIRUS INFECTIONS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS; VIRAL VACCINES;

EID: 84964068412     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2016.1167603     Document Type: Review

References (134)

1. M.Ki 2015 MERS outbreak in Korea:hospital-to-hospital transmission. Epidemiol Health. 2015;37:e2015033.
2. A.M.Zaki, S.van Boheemen, T.M.Bestebroer, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.•• First report on the isolation of Middle East respiratory syndrome coronavirus (MERS-CoV) in humans.
3. WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). 2016. [cited 2016 Feb2]. Available from: http://www.who.int/emergencies/mers-cov/en/.
4. MERS-CoV daily update. 2016. [cited 2016 Feb24]. Available from: http://www.moh.gov.sa/en/CCC/PressReleases/Pages/default.aspx
5. W.Li, Z.Shi, M.Yu, et al. Bats are natural reservoirs of SARS-like coronaviruses. Science. 2005;310(5748):676–679.
6. Y.W.Huang, A.W.Dickerman, P.Pineyro, et al. Origin, evolution, and genotyping of emergent porcine epidemic diarrhea virus strains in the United States. MBio. 2013;4(5):e00737–13.
7. G.Lu, Q.Wang, G.F.Gao. Bat-to-human:spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23(8):468–478.
8. Y.Yang, L.Du, C.Liu, et al. Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014;111(34):12516–12521.
9. Y.Yang, C.Liu, L.Du, et al. Two mutations were critical for bat-to-human transmission of Middle East respiratory syndrome coronavirus. J Virol. 2015;89(17):9119–9123.
10. Z.A.Memish, N.Mishra, K.J.Olival, et al. Middle East respiratory syndrome coronavirus in bats, Saudi Arabia. Emerg Infect Dis. 2013;19(11):1819–1823.
11. L.Du, Y.He, Y.Zhou, et al. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009;7(3):226–236.
12. Y.Guan, B.J.Zheng, Y.Q.He, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China. Science. 2003;302(5643):276–278.
13. A.N.Alagaili, T.Briese, N.Mishra, et al. Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. MBio. 2014;5(2):e00884–14.
14. M.A.Muller, B.Meyer, V.M.Corman, et al. Presence of Middle East respiratory syndrome coronavirus antibodies in Saudi Arabia:a nationwide, cross-sectional, serological study. Lancet Infect Dis. 2015;15(5):559–564.
15. T.Briese, N.Mishra, K.Jain, et al. Middle East respiratory syndrome coronavirus quasispecies that include homologues of human isolates revealed through whole-genome analysis and virus cultured from dromedary camels in Saudi Arabia. MBio. 2014;5(3):e01146–14.
16. D.R.Adney, N.van Doremalen, V.R.Brown, et al. Replication and shedding of MERS-CoV in upper respiratory tract of inoculated dromedary camels. Emerg Infect Dis. 2014;20(12):1999–2005.
17. J.S.Sabir, T.T.Lam, M.M.Ahmed, et al. Co-circulation of three camel coronavirus species and recombination of MERS-CoVs in Saudi Arabia. Science. 2016;351(6268):81–84.
18. J.Y.Choi. An outbreak of Middle East respiratory syndrome coronavirus infection in South Korea, 2015. Yonsei Med J. 2015;56(5):1174–1176.
19. S.S.Lee, N.S.Wong. Probable transmission chains of Middle East respiratory syndrome coronavirus and the multiple generations of secondary infection in South Korea. Int J Infect Dis. 2015;38:65–67.
20. I.K.Oboho, S.M.Tomczyk, A.M.Al-Asmari, et al. 2014 MERS-CoV outbreak in Jeddah–a link to health care facilities. N Engl J Med. 2015;372(9):846–854.
21. A.Assiri, A.McGeer, T.M.Perl, et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407–416.
22. Z.A.Memish, J.A.Al-Tawfiq, R.F.Alhakeem, et al. Middle East respiratory syndrome coronavirus (MERS-CoV):A cluster analysis with implications for global management of suspected cases. Travel Med Infect Dis. 2015;13(4):311–314.
23. Z.A.Memish, A.I.Zumla, R.F.Al-Hakeem, et al. Family cluster of Middle East respiratory syndrome coronavirus infections. N Engl J Med. 2013;368(26):2487–2494.
24. A.S.Omrani, M.A.Matin, Q.Haddad, et al. A family cluster of Middle East respiratory syndrome coronavirus infections related to a likely unrecognized asymptomatic or mild case. Int J Infect Dis. 2013;17(9):e668–672.
25. F.Abroug, A.Slim, L.Ouanes-Besbes, et al. Family cluster of Middle East respiratory syndrome coronavirus infections, Tunisia, 2013. Emerg Infect Dis. 2014;20(9):1527–1530.
26. NIAID Emerging Infectious Diseases/Pathogens. 2015. [cited 2015 Feb25]. Available from: https://www.niaid.nih.gov/topics/biodefenserelated/biodefense/pages/cata.aspx
27. N.Zhang, S.Jiang, L.Du. Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014;13(6):761–774.
28. P.C.Woo, S.K.Lau, C.S.Lam, et al. Discovery of seven novel Mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J Virol. 2012;86(7):3995–4008.
29. V.D.Menachery, B.L.YountJr, K.Debbink, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat Med. 2015;21(12):1508–1513.
30. X.Y.Ge, J.L.Li, X.L.Yang, et al. Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature. 2013;503(7477):535–538.
31. Y.Ma, Y.Zhang, X.Liang, et al. Origin, evolution, and virulence of porcine deltacoronaviruses in the United States. MBio. 2015;6(2):e00064.
32. L.Wang, B.Byrum, Y.Zhang. Detection and genetic characterization of deltacoronavirus in pigs, Ohio, USA, 2014. Emerg Infect Dis. 2014;20(7):1227–1230.
33. D.Marthaler, L.Raymond, Y.Jiang, et al. Rapid detection, complete genome sequencing, and phylogenetic analysis of porcine deltacoronavirus. Emerg Infect Dis. 2014;20(8):1347–1350.
34. H.Hu, K.Jung, A.N.Vlasova, et al. Isolation and characterization of porcine deltacoronavirus from pigs with diarrhea in the United States. J Clin Microbiol. 2015;53(5):1537–1548.
35. A.Bonavia, B.D.Zelus, D.E.Wentworth, et al. Identification of a receptor-binding domain of the spike glycoprotein of human coronavirus HCoV-229E. J Virol. 2003;77(4):2530–2538.
36. H.Hofmann, K.Pyrc, L.van der Hoek, et al. Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc Natl Acad Sci U S A. 2005;102(22):7988–7993.
37. S.K.Lau, P.C.Woo, C.C.Yip, et al. Coronavirus HKU1 and other coronavirus infections in Hong Kong. J Clin Microbiol. 2006;44(6):2063–2071.
38. N.S.Zhong, B.J.Zheng, Y.M.Li, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362(9393):1353–1358.
39. S.McIntosh Assessing the South Korea MERS outbreak:could it happen elsewhere. 2015. [cited 2015 Jul30]. Available from: http://www.medicalnewstoday.com/articles/297535.php
40. S.Su, G.Wong, Y.Liu, et al. MERS in South Korea and China:a potential outbreak threat? Lancet. 2015;385(9985):2349–2350.
41. J.F.Chan, K.S.Li, K.K.To, et al. Is the discovery of the novel human betacoronavirus 2c EMC/2012 (HCoV-EMC) the beginning of another SARS-like pandemic? J Infect. 2012;65(6):477–489.
42. J.F.Chan, S.K.Lau, P.C.Woo. The emerging novel Middle East respiratory syndrome coronavirus:the “knowns” and “unknowns”. J Formos Med Assoc. 2013;112(7):372–381.
43. S.van Boheemen, M.de Graaf, C.Lauber, et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. MBio. 2012;3(6):pii:e00473–12.
44. Q.Wang, J.Qi, Y.Yuan, et al. Bat origins of MERS-CoV supported by bat coronavirus HKU4 usage of human receptor CD26. Cell Host Microbe. 2014;16(3):328–337.
45. V.S.Raj, H.Mou, S.L.Smits, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495(7440):251–254.• First report on the identification of MERS-CoV’s receptor dipeptidyl peptidase 4 (DPP4).
46. T.Scobey, B.L.Yount, A.C.Sims, et al. Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A. 2013;110(40):16157–16162.
47. F.Almazán, M.L.DeDiego, I.Sola, et al. Engineering a replication-competent, propagation-defective Middle East respiratory syndrome coronavirus as a vaccine candidate. MBio. 2013;4(5):e00650–13.
48. F.Li. Receptor recognition mechanisms of coronaviruses:a decade of structural studies. J Virol. 2015;89(4):1954–1964.
49. L.Lu, Q.Liu, Y.Zhu, et al. Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014;5:3067.
50. J.Gao, G.Lu, J.Qi, et al. Structure of the fusion core and inhibition of fusion by a heptad-repeat peptide derived from the S protein of MERS-CoV. J Virol. 2013;87:13134–13140.
51. N.Wang, X.Shi, L.Jiang, et al. Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 2013;23(8):986–993.
52. Y.Chen, K.R.Rajashankar, Y.Yang, et al. Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol. 2013;87(19):10777–10783.
53. G.Lu, Y.Hu, Q.Wang, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500(7461):227–231.
54. F.Li, W.Li, M.Farzan, et al. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005;309(5742):1864–1868.
55. B.L.Haagmans, S.H.Al Dhahiry, C.B.Reusken, et al. Middle East respiratory syndrome coronavirus in dromedary camels:an outbreak investigation. Lancet Infect Dis. 2014;14(2):140–145.
56. C.B.Reusken, M.Ababneh, V.S.Raj, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013. Euro Surveill. 2013;18(50):20662.
57. W.B.Park, R.A.Perera, P.G.Choe, et al. Kinetics of serologic responses to MERS coronavirus infection in humans, South Korea. Emerg Infect Dis. 2015;21(12):2186–2189.
58. M.G.Hemida, R.A.Perera, R.A.Al Jassim, et al. Seroepidemiology of Middle East respiratory syndrome (MERS) coronavirus in Saudi Arabia (1993) and Australia (2014) and characterisation of assay specificity. Euro Surveill. 2014;19(23):pii:20828.
59. S.W.Park, R.A.Perera, P.G.Choe, et al. Comparison of serological assays in human Middle East respiratory syndrome (MERS)-coronavirus infection. Euro Surveill. 2015;20:41.
60. C.B.Reusken, B.L.Haagmans, M.A.Muller, et al. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels:a comparative serological study. Lancet Infect Dis. 2013;13(10):859–866.
61. V.M.Corman, A.M.Albarrak, A.S.Omrani, et al. Viral shedding and antibody response in 37 patients with Middle East respiratory syndrome coronavirus infection. Clin Infect Dis. 2016;62(4):477–483.
62. E.Faure, J.Poissy, A.Goffard, et al. Distinct immune response in two MERS-CoV-infected patients:can we go from bench to bedside? PLoS One. 2014;9(2):e88716.
63. H.Chu, J.Zhou, B.H.Wong, et al. Productive replication of Middle East respiratory syndrome coronavirus in monocyte-derived dendritic cells modulates innate immune response. Virology. 2014;454–455:197–205.
64. B.L.Haagmans, J.M.Van Den Brand, V.S.Raj, et al. An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science. 2016;351(6268):77–81.•• A report about the protective immunity of a viral vector modified vaccinia virus Ankara (MVA)-based, spike-protein-expressing vaccine against MERS-CoV challenge in dromedary camels.
65. C.Ma, Y.Li, L.Wang, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization:Implication for designing novel mucosal MERS vaccines. Vaccine. 2014;32(18):2100–2108.
66. C.Ma, L.Wang, X.Tao, et al. Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments – the importance of immunofocusing in subunit vaccine design. Vaccine. 2014;32(46):6170–6176.•• A report about the identification of a critical neutralizing domain fragment in MERS-CoV receptor-binding domain (RBD) as a vaccine target.
67. L.Du, Z.Kou, C.Ma, et al. A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses:implication for developing therapeutics and vaccines. PLoS One. 2013;8(12):e81587.
68. N.Zhang, J.Tang, L.Lu, et al. Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015;202:151–159.
69. W.Ise. Development and function of follicular helper T cells. Biosci Biotechnol Biochem. 2015;80(1):1–6.
70. K.Muthumani, D.Falzarano, E.L.Reuschel, et al. A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates. Sci Transl Med. 2015;7(301):301ra132.•• A report about the protective efficacy of a MERS-CoV full-length spike-based DNA vaccine in NHPs.
71. J.Lan, Y.Deng, H.Chen, et al. Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One. 2014;9(11):e112602.
72. A.H.Malczyk, A.Kupke, S.Prufer, et al. A highly immunogenic and protective Middle East respiratory syndrome coronavirus vaccine based on a recombinant Measles virus vaccine platform. J Virol. 2015;89(22):11654–11667.
73. X.Tao, T.Garron, A.S.Agrawal, et al. Characterization and demonstration of value of a lethal mouse model of Middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;90(1):57–67.
74. N.Zhang, R.Channappanavar, C.Ma, et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2015. doi:10.1038/cmi.2015.03.
75. L.Du, S.Jiang. Middle East respiratory syndrome:current status and future prospects for vaccine development. Expert Opin Biol Ther. 2015;15(11):1647–1651.
76. N.van Doremalen, V.J.Munster. Animal models of Middle East respiratory syndrome coronavirus infection. Antiviral Res. 2015;122:28–38.
77. E.De Wit, A.L.Rasmussen, D.Falzarano, et al. Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A. 2013;110(41):16598–16603.
78. Y.Yao, L.Bao, W.Deng, et al. An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. J Infect Dis. 2014;209(2):236–242.
79. D.Falzarano, E.De Wit, F.Feldmann, et al. Infection with MERS-CoV causes lethal pneumonia in the common marmoset. PLoS Pathog. 2014;10(8):e1004250.
80. K.Li, C.Wohlford-Lenane, S.Perlman, et al. Middle East respiratory syndrome coronavirus causes multiple organ damage and lethal disease in mice transgenic for human dipeptidyl peptidase 4. J Infect Dis. 2016;213(5):712–722.
81. G.Zhao, Y.Jiang, H.Qiu, et al. Multi-organ damage in human dipeptidyl peptidase 4 transgenic mice infected with Middle East respiratory syndrome-coronavirus. PLoS One. 2015;10(12):e0145561.
82. A.S.Agrawal, T.Garron, X.Tao, et al. Generation of a transgenic mouse model of middle East respiratory syndrome coronavirus infection and disease. J Virol. 2015;89(7):3659–3670.• First report on the generation of a MERS-CoV transgenic mouse model.
83. J.Zhao, K.Li, C.Wohlford-Lenane, et al. Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A. 2014;111(13):4970–4975.
84. L.Wang, L.Shi, M.G.Joyce, et al. Evaluation of candidate vaccine approaches for MERS-CoV. Nat Commun. 2015;6:7712.• A report about employing DNA priming and protein boosting strategy in developing MERS vaccines.
85. B.L.Haagmans, J.M.Van Den Brand, L.B.Provacia, et al. Asymptomatic Middle East respiratory syndrome coronavirus infection in rabbits. J Virol. 2015;89(11):6131–6135.
86. K.E.Pascal, C.M.Coleman, A.O.Mujica, et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc Natl Acad Sci U S A. 2015;112(28):8738–8743.
87. R.F.Johnson, L.E.Via, M.R.Kumar, et al. Intratracheal exposure of common marmosets to MERS-CoV Jordan-n3/2012 or MERS-CoV EMC/2012 isolates does not result in lethal disease. Virology. 2015;485:422–430.
88. A.Roberts, L.Vogel, J.Guarner, et al. Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol. 2005;79(1):503–511.
89. Y.K.Chu, G.D.Ali, F.Jia, et al. The SARS-CoV ferret model in an infection-challenge study. Virology. 2008;374(1):151–163.
90. M.E.Darnell, E.P.Plant, H.Watanabe, et al. Severe acute respiratory syndrome coronavirus infection in vaccinated ferrets. J Infect Dis. 2007;196(9):1329–1338.
91. A.Roberts, C.Paddock, L.Vogel, et al. Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol. 2005;79(9):5833–5838.
92. E.De Wit, J.Prescott, L.Baseler, et al. The Middle East respiratory syndrome coronavirus (MERS-CoV) does not replicate in Syrian hamsters. PLoS One. 2013;8(7):e69127.
93. N.van Doremalen, K.L.Miazgowicz, S.Milne-Price, et al. Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol. 2014;88(16):9220–9232.
94. A.S.Cockrell, K.M.Peck, B.L.Yount, et al. Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol. 2014;88(9):5195–5199.
95. C.M.Coleman, K.L.Matthews, L.Goicochea, et al. Wild-type and innate immune-deficient mice are not susceptible to the Middle East respiratory syndrome coronavirus. J Gen Virol. 2014;95(Pt 2):408–412.
96. C.M.Coleman, Y.V.Liu, H.Mu, et al. Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice. Vaccine. 2014;32(26):3169–3174.• A report on the development of nanoparticle-based MERS vaccines.
97. E.Kim, K.Okada, T.Kenniston, et al. Immunogenicity of an adenoviral-based Middle East respiratory syndrome coronavirus vaccine in BALB/c mice. Vaccine. 2014;32(45):5975–5982.
98. FDA approves first in-human study of MERS vaccine. 2015. [cited 2015 Nov23]. Available from: http://vaccinenewsdaily.com/stories/510649306-fda-approves-first-in-human-study-of-mers-vaccine.
99. München. Drying out the reservoir. 2015. [cited 2015 Dec28]. Available from: https://www.en.uni-muenchen.de/news/newsarchiv/2015/sutter_mers_camels.html
100. F.Song, R.Fux, L.B.Provacia, et al. Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. J Virol. 2013;87(21):11950–11954.
101. A.Volz, A.Kupke, F.Song, et al. Protective efficacy of recombinant modified vaccinia virus Ankara delivering Middle East respiratory syndrome coronavirus spike glycoprotein. J Virol. 2015;89(16):8651–8656.
102. X.Guo, Y.Deng, H.Chen, et al. Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus. Immunology. 2015;145(4):476–484.
103. J.Lan, Y.Yao, Y.Deng, et al. Recombinant receptor binding domain protein induces partial protective immunity in Rhesus Macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine. 2015;2(10):1438–1446.
104. J.Tang, N.Zhang, X.Tao, et al. Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015;11(5):1244–1250.
105. L.Tang, Q.Zhu, E.Qin, et al. Inactivated SARS-CoV vaccine prepared from whole virus induces a high level of neutralizing antibodies in BALB/c mice. DNA Cell Biol. 2004;23(6):391–394.
106. N.Takasuka, H.Fujii, Y.Takahashi, et al. A subcutaneously injected UV-inactivated SARS coronavirus vaccine elicits systemic humoral immunity in mice. Int Immunol. 2004;16(10):1423–1430.
107. J.Zhou, W.Wang, Q.Zhong, et al. Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine. 2005;23(24):3202–3209.
108. J.M.Jimenez-Guardeno, J.A.Regla-Nava, J.L.Nieto-Torres, et al. Identification of the mechanisms causing reversion to virulence in an attenuated SARS-CoV for the design of a genetically stable vaccine. PLoS Pathog. 2015;11(10):e1005215.
109. M.Faber, E.W.Lamirande, A.Roberts, et al. A single immunization with a rhabdovirus-based vector expressing severe acute respiratory syndrome coronavirus (SARS-CoV) S protein results in the production of high levels of SARS-CoV-neutralizing antibodies. J Gen Virol. 2005;86(Pt 5):1435–1440.
110. M.Liniger, A.Zuniga, A.Tamin, et al. Induction of neutralising antibodies and cellular immune responses against SARS coronavirus by recombinant measles viruses. Vaccine. 2008;26(17):2164–2174.
111. G.P.Kobinger, J.M.Figueredo, T.Rowe, et al. Adenovirus-based vaccine prevents pneumonia in ferrets challenged with the SARS coronavirus and stimulates robust immune responses in macaques. Vaccine. 2007;25(28):5220–5231.
112. A.Pandey, N.Singh, S.V.Vemula, et al. Impact of preexisting adenovirus vector immunity on immunogenicity and protection conferred with an adenovirus-based H5N1 influenza vaccine. PLoS One. 2012;7(3):e33428.
113. K.McCoy, N.Tatsis, B.Korioth-Schmitz, et al. Effect of preexisting immunity to adenovirus human serotype 5 antigens on the immune responses of nonhuman primates to vaccine regimens based on human- or chimpanzee-derived adenovirus vectors. J Virol. 2007;81(12):6594–6604.
114. L.H.Haut, S.Ratcliffe, A.R.Pinto, et al. Effect of preexisting immunity to adenovirus on transgene product-specific genital T cell responses on vaccination of mice with a homologous vector. J Infect Dis. 2011;203(8):1073–1081.
115. M.Czub, H.Weingartl, S.Czub, et al. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine. 2005;23(17–18):2273–2279.
116. H.Weingartl, M.Czub, S.Czub, et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004;78(22):12672–12676.
117. M.Jaume, M.S.Yip, Y.W.Kam, et al. SARS CoV subunit vaccine:antibody-mediated neutralisation and enhancement. Hong Kong Med J. 2012;18(Suppl 2):31–36.
118. Z.Y.Yang, W.P.Kong, Y.Huang, et al. A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature. 2004;428(6982):561–564.
119. H.Mou, V.S.Raj, F.J.van Kuppeveld, et al. The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013;87(16):9379–9383.
120. L.Du, G.Zhao, Z.Kou, et al. Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013;87(17):9939–9942.
121. L.Du, G.Zhao, Y.Yang, et al. A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014;88(12):7045–7053.
122. R.Chlibek, K.Pauksens, L.Rombo, et al. Long-term immunogenicity and safety of an investigational herpes zoster subunit vaccine in older adults. Vaccine. 2016;34(6):863–868.
123. E.M.Berkowitz, G.Moyle, H.J.Stellbrink, et al. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults:a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211(8):1279–1287.
124. P.Durando, D.Fenoglio, A.Boschini, et al. Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults. Clin Vaccine Immunol. 2008;15(2):253–259.
125. NIH. 2012. [cited 2012 Apr3]. Available from: https://www.niaid.nih.gov/topics/vaccines/Pages/typesVaccines.aspx#subunit.
126. WHO. Subunit vaccines. 2015. [cited 2015]. Available from: http://vaccine-safety-training.org/subunit-vaccines.html
127. L.Du, G.Zhao, L.Li, et al. Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009;384(4):486–490.
128. L.Du, G.Zhao, C.C.Chan, et al. Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009;393(1):144–150.
129. S.Jiang, M.E.Bottazzi, L.Du, et al. Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012;11(12):1405–1413.
130. Y.He, Q.Zhu, S.Liu, et al. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus:importance for designing SARS vaccines. Virology. 2005;334(1):74–82.
131. L.Du, G.Zhao, Y.He, et al. Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007;25(15):2832–2838.
132. Y.He, J.Li, W.Li, et al. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J Immunol. 2006;176(10):6085–6092.
133. W.H.Chen, L.Du, S.M.Chag, et al. Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014;10(3):648–658.
134. D.Corti, J.Zhao, M.Pedotti, et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc Natl Acad Sci U S A. 2015;112(33):10473–10478.